November 2019; Annals of Oncology IMbrave150 Efficacy and safety results from a ph III study evaluating atezolizumab atezo bevacizumab bev vs sorafenib Sor as first treatment tx for patients pts with unresectable hepatocellular carcinoma HCC Author affiliated institutions include National Taiwan University Cancer Center Taiwan, People s Liberation Army Cancer Center China, National Cancer Center Hospital East Japan, University Medical Center Mainz Germany, Harvard Medical School USA, N
lasix iv dose